4Monnier L,Lapinski H,Colette C.Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycem of type 2 diabetic patiens variations with increasing levels of HbAlc.Daibetes Care,2003,26(3):881-885.
5Bode BW,Strange P.Efficacy,safety,and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes.Diabetes Care,2001,24:69-72.
4Kokic S, Bukovic D, Radman M,et al. Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure [ J ]. Coil Antropol,2003,27 ( 1 ) : 181 - 187.
5Bastyr EJ III, Stuart CA, Brodows RG,et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior fur lowering HbA1 c. IOEZ Study Group[ J]. Diabetes Care,2000, 23:1236 - 1241.
6Ahuntas Y, Ozen B, Ozturk B, et al. Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure.[ J]. Diabetes Obes Metab,2003, 5 (6) :371 - 378.
7Hedman CA, Lindstrom T, Arnqvist HI. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection Jn type 1 diabetes[ J]. Diabetes Care,2001,24(6) :1120 - 1121.
8von Mach MA, Brinkmann C, Hansen T, et al. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers [ J ]. Exp Clin Endocrinol Diabetes, 2002,110 (8) :416 -419.
9Kurtzhals P,Schaffer L, Sφrensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use[ J ]. Diabetes ,2000,49 (6) :999 -1005.
10Wyatt JW,Frias JL, Hoyme HE, et al. Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy[ J ]. Diabete Med ,2005,22 (6) :803 - 807.
